• CSR Summary
• NCT00524043
• Primary Citation
• Data Specification

Approved Data Requests Associated with this Trial

• 2024-0608 : Understanding treatment effects and symptom dynamics in schizophrenia using network analysis
• 2024-0280 : Individual-level and study-level predictors of placebo response and dropout in Schizophrenia Disorder clinical trials
• 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
• 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
• 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
• 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
• 2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis
• 2021-4568 : Motor side effects and antipsychotic efficacy of antipsychotic drugs: An individual participant meta-analysis
• 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
• 2019-3941 : Factors moderating estimates of antipsychotic efficacy in schizophrenia
• 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
• 2019-3821 : Variability in antipsychotic response
• 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
• 2017-1676 : Placebo Effects in Schizophrenia
• 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis